On April 30, 2025 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported its participation in the H.C. Wainwright 3rd Annual BioConnect Investor Conference, to be held on May 20, 2025, at Nasdaq World Headquarters in New York City (Press release, Anixa Biosciences, APR 30, 2025, View Source [SID1234652376]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Catelani, President and CFO of Anixa, will deliver a presentation and will be available for one-on-one meetings during the conference.

Details of the presentation are as follows:

Event: H.C. Wainwright 3rd Annual BioConnect Investor Conference
Date: May 20, 2025
Time: 11:00 AM ET
Location: Nasdaq World Headquarters in New York City
Webcast: View Source

On April 30, 2025 Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for oncology and neurological disorders, reported that preclinical data will be presented on its proprietary RSwitch technology, which enables the fine-tuning of transgene levels in gene and cell therapy applications, at the American Society of Gene And Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 28th Annual Meeting, which will be held from May 13 -17th, 2025, in New Orleans, LA (Press release, Rgenta Therapeutics, APR 30, 2025, View Source [SID1234652396]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: RSwitch Enabled Gene Therapy to Fine Tune Frataxin Expression for the Treatment of Friedrich’s Ataxia
Authors: Samuel A. Hasson, Jon Dempersmier, Mariam Elhawary, Diane Hamann, Ian McLachlan, Chris Yates, Travis Wager, and Simon Xi
Session date and time: Wednesday, May 14, 2025, 5:30 – 7:00 PM CT
Location: Poster Hall I2
Poster ID: AMA251

About RSwitch
RSwitch is a proprietary regulatable gene therapy system that enables oral, small molecule drug control of transgene levels in gene and cell therapy applications. RSwitch encodes a "dimmer" switch that makes the expression of transgene dependent on the administration of an oral small molecule drug that controls the system. Only when the drug is administered is the system activated. Furthermore, the level of gene expression is dependent on how much drug is administered. This precise gene control has the potential to enable fine control of the expression of a therapeutic protein. Rgenta has demonstrated the RSwitch system’s feasibility in vitro and in vivo, achieving dose-dependent expression of reporter transgenes following small molecule administration. RSwitch technology offers versatile control across multiple gene and cell therapy applications, and the company is actively exploring strategic partnerships.

On April 30, 2025 Imugene reported results for quarter ended March 2025 (Presentation, Imugene, APR 30, 2025, View Source [SID1234654357]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 30, 2025 Nain Biotech reported the company presents World-First R&D Results at AACR (Free AACR Whitepaper) 2025 Chicago (Press release, Nain Biotech, APR 30, 2025, View Source [SID1234654627]). This international conference, steeped in a century of academic heritage, once again captured global attention with its groundbreaking themes and unprecedented attendance. According to official data, the conference brought together over 20,000 leading oncology scholars, clinicians, and industry representatives from over 60 countries. They engaged in in-depth discussions on cutting-edge fields such as precision medicine, immunotherapy, and gene editing, exploring more feasible technological approaches to advance humanity’s fight against cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On April 30, 2025 Aveta Biomics, a clinicalstage biotechnology company developing first-in-class drugs that reprogram the immune system to fight cancer, reported acceptance of abstract for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 30 – June 3, 2025, in Chicago, Illinois (Press release, Aveta Biomics, APR 30, 2025, View Source [SID1234652377]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster will feature clinical data from the company’s Phase IIA trial evaluating its drug APG157 as a neoadjuvant monotherapy in patients with locally advanced squamous cell carcinoma of the head and neck.

"The acceptance of our Phase IIA data for presentation at ASCO (Free ASCO Whitepaper) marks an important milestone for Aveta Biomics," said Parag Mehta, Ph.D., Chief Executive Officer of Aveta Biomics. "We look forward to sharing the full dataset with the oncology community and advancing APG-157 toward a pivotal trial in head and neck cancer."

"APG-157 has the potential to become a first-in-class, practice-changing neoadjuvant therapy for patients with locally advanced head and neck cancer," said Selda Samakoglu, M.D., Ph.D., Chief Medical Officer of Aveta Biomics. "In our Phase IIA study, APG-157 demonstrated clinically meaningful activity across multiple key endpoints, including survival outcomes, with consistent benefits observed both in the overall patient population and in key subgroups. We look forward to advancing APG-157 into a pivotal trial, with the goal of confirming these promising results and establishing APG-157 as a transformative monotherapy option in this setting."

PRESENTATION DETAILS:

TITLE: Neoadjuvant APG-157 monotherapy in patients with locally advanced squamous cell carcinoma of head and neck: A phase IIA, single arm trial
ABSTRACT NUMBER: 6087
POSTER BOARD 495
SESSION TITLE: Head and Neck Cancer
SESSION DATE AND TIME: June 2, 2025, 9:00 AM – 12:00 PM CDT

PRESENTERS:
• Marilene Wang, M.D., Professor, Department of Head and Neck Surgery, UCLA David Geffen School of Medicine and VA Hospital of Greater Los Angeles
• Elizabeth Franzmann, M.D., Professor, Head and Neck Surgery, University of Miami, Sylvester Comprehensive Cancer Center